Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Has A Couple Of Controversies To Cover During Earnings Call

Executive Summary

Q1 Earnings Preview: From troubling safety data for tanezumab to pressure on insulin prices, Lilly is likely to face questions about controversies in its R&D pipeline and commercial portfolio during its first quarter earnings call on April 30. 

Related Content

Lilly Says Volume Growth Strategy, Launches Working Despite Price Pressures
Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results
Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform
Same Drug, Two Versions And Prices, This Time For Lilly's Humalog
Industry's Drug Pricing Power Is Running On Fumes
Lilly Sees New Product Gains, But Older Drugs Still Limit Growth Potential
Lartruvo Phase III Fail Rocks Lilly Oncology Plans
Lift-Off For Lilly In Cancer Genetics With Loxo Buy
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts